| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sentinel Lymph Node Biopsy | 28 | 2024 | 1415 | 4.300 |
Why?
|
| Lymph Node Excision | 27 | 2024 | 1959 | 4.110 |
Why?
|
| Breast Neoplasms | 73 | 2024 | 15694 | 3.870 |
Why?
|
| Axilla | 30 | 2024 | 902 | 3.870 |
Why?
|
| Neoadjuvant Therapy | 35 | 2024 | 4975 | 3.300 |
Why?
|
| Lymph Nodes | 20 | 2024 | 2967 | 2.960 |
Why?
|
| Carcinoma, Lobular | 11 | 2021 | 611 | 2.180 |
Why?
|
| Carcinoma, Ductal, Breast | 15 | 2021 | 1216 | 2.030 |
Why?
|
| Sentinel Lymph Node | 7 | 2023 | 216 | 1.980 |
Why?
|
| Mastectomy, Segmental | 18 | 2023 | 1026 | 1.750 |
Why?
|
| Mastectomy | 18 | 2023 | 1534 | 1.340 |
Why?
|
| Lymphatic Metastasis | 24 | 2024 | 4844 | 1.340 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 1303 | 1.140 |
Why?
|
| Neoplasm Staging | 31 | 2024 | 13658 | 1.080 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2020 | 3890 | 0.850 |
Why?
|
| Lymphedema | 1 | 2023 | 239 | 0.720 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 9 | 2021 | 674 | 0.700 |
Why?
|
| Female | 78 | 2024 | 141928 | 0.640 |
Why?
|
| Mammaplasty | 6 | 2022 | 780 | 0.620 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2011 | 607 | 0.570 |
Why?
|
| Drug Monitoring | 1 | 2018 | 333 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 2403 | 0.570 |
Why?
|
| Humans | 89 | 2024 | 261506 | 0.510 |
Why?
|
| Nomograms | 2 | 2016 | 313 | 0.500 |
Why?
|
| Prognosis | 26 | 2021 | 21713 | 0.490 |
Why?
|
| Postoperative Complications | 7 | 2020 | 5542 | 0.490 |
Why?
|
| Surgeons | 3 | 2019 | 519 | 0.480 |
Why?
|
| Decision Making | 5 | 2020 | 1287 | 0.480 |
Why?
|
| Middle Aged | 49 | 2024 | 86204 | 0.450 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2023 | 2231 | 0.440 |
Why?
|
| Aged | 44 | 2024 | 70117 | 0.440 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 255 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 551 | 0.430 |
Why?
|
| Adult | 42 | 2021 | 77950 | 0.410 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 14889 | 0.410 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14289 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2021 | 10035 | 0.390 |
Why?
|
| Receptors, Estrogen | 7 | 2024 | 2086 | 0.380 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 1215 | 0.350 |
Why?
|
| Surgical Instruments | 2 | 2021 | 138 | 0.340 |
Why?
|
| Time-to-Treatment | 3 | 2020 | 292 | 0.340 |
Why?
|
| Prospective Studies | 12 | 2024 | 12873 | 0.340 |
Why?
|
| Medical Oncology | 1 | 2017 | 1423 | 0.330 |
Why?
|
| Aged, 80 and over | 23 | 2019 | 29902 | 0.330 |
Why?
|
| Printing, Three-Dimensional | 2 | 2021 | 129 | 0.330 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 7789 | 0.320 |
Why?
|
| Ultrasonography | 5 | 2019 | 1863 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 15862 | 0.320 |
Why?
|
| Receptor, ErbB-2 | 8 | 2024 | 2518 | 0.310 |
Why?
|
| Parathyroidectomy | 2 | 2006 | 203 | 0.310 |
Why?
|
| Combined Modality Therapy | 12 | 2019 | 8865 | 0.310 |
Why?
|
| Oncologists | 2 | 2019 | 134 | 0.300 |
Why?
|
| Health Plan Implementation | 2 | 2019 | 90 | 0.290 |
Why?
|
| Mastectomy, Simple | 2 | 2016 | 58 | 0.280 |
Why?
|
| False Negative Reactions | 2 | 2017 | 275 | 0.280 |
Why?
|
| Survival Rate | 12 | 2016 | 12221 | 0.270 |
Why?
|
| RNA, Long Noncoding | 2 | 2023 | 598 | 0.270 |
Why?
|
| Feasibility Studies | 4 | 2021 | 2292 | 0.260 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 264 | 0.250 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 185 | 0.250 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 1742 | 0.250 |
Why?
|
| Receptors, Progesterone | 4 | 2016 | 1392 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 262 | 0.250 |
Why?
|
| Registries | 3 | 2024 | 2170 | 0.240 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 610 | 0.240 |
Why?
|
| Skin Neoplasms | 3 | 2011 | 4654 | 0.230 |
Why?
|
| RNA, Small Nucleolar | 1 | 2023 | 25 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2011 | 806 | 0.230 |
Why?
|
| Adenoma | 2 | 2019 | 716 | 0.230 |
Why?
|
| Melanoma | 3 | 2011 | 5317 | 0.220 |
Why?
|
| Lipolysis | 1 | 2023 | 108 | 0.220 |
Why?
|
| Kynurenine | 1 | 2023 | 71 | 0.220 |
Why?
|
| Quality Improvement | 2 | 2019 | 851 | 0.210 |
Why?
|
| Treatment Outcome | 13 | 2021 | 32848 | 0.200 |
Why?
|
| Patient Selection | 4 | 2020 | 2055 | 0.200 |
Why?
|
| Magnetic Phenomena | 1 | 2021 | 26 | 0.200 |
Why?
|
| Lymphoscintigraphy | 1 | 2020 | 35 | 0.190 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2020 | 37 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2006 | 600 | 0.190 |
Why?
|
| Prophylactic Mastectomy | 1 | 2020 | 35 | 0.190 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.180 |
Why?
|
| Upper Extremity | 1 | 2020 | 87 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| Retrospective Studies | 18 | 2020 | 37905 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 1371 | 0.170 |
Why?
|
| Accreditation | 1 | 2019 | 126 | 0.170 |
Why?
|
| Perforator Flap | 1 | 2020 | 93 | 0.170 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 160 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 3719 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2019 | 272 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 690 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2020 | 190 | 0.160 |
Why?
|
| Societies, Medical | 3 | 2014 | 1335 | 0.160 |
Why?
|
| Radiotherapy | 2 | 2023 | 1824 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 6 | 2015 | 3981 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2019 | 251 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.150 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2006 | 1330 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2018 | 259 | 0.150 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 446 | 0.150 |
Why?
|
| Postmenopause | 3 | 2024 | 378 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2023 | 650 | 0.140 |
Why?
|
| Sarcoma | 1 | 2006 | 1725 | 0.140 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.140 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 270 | 0.140 |
Why?
|
| Oncogenes | 1 | 2019 | 673 | 0.140 |
Why?
|
| Young Adult | 13 | 2020 | 21445 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 622 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 327 | 0.130 |
Why?
|
| Parathyroid Hormone | 2 | 2006 | 194 | 0.130 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 167 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2019 | 636 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 321 | 0.130 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.130 |
Why?
|
| Cross Infection | 1 | 2019 | 544 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2016 | 182 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 700 | 0.120 |
Why?
|
| Trastuzumab | 2 | 2018 | 696 | 0.120 |
Why?
|
| Preoperative Care | 3 | 2020 | 1529 | 0.120 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2014 | 185 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 234 | 0.110 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 1656 | 0.110 |
Why?
|
| Morbidity | 1 | 2014 | 397 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 1209 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.110 |
Why?
|
| Analgesics | 1 | 2016 | 390 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2023 | 5061 | 0.110 |
Why?
|
| Margins of Excision | 3 | 2020 | 285 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.100 |
Why?
|
| Calcinosis | 1 | 2015 | 423 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 415 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1724 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 410 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2016 | 451 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 5112 | 0.100 |
Why?
|
| Mammography | 4 | 2020 | 1010 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2021 | 10001 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2016 | 674 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2021 | 9244 | 0.090 |
Why?
|
| Carney Complex | 1 | 2010 | 7 | 0.090 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2010 | 95 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 450 | 0.090 |
Why?
|
| Keratinocytes | 1 | 2010 | 241 | 0.090 |
Why?
|
| Intraoperative Period | 2 | 2006 | 246 | 0.090 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 183 | 0.090 |
Why?
|
| United States | 5 | 2020 | 15433 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 4849 | 0.080 |
Why?
|
| Anthracyclines | 1 | 2010 | 331 | 0.080 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2009 | 169 | 0.080 |
Why?
|
| Interleukins | 1 | 2010 | 325 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 716 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2023 | 7226 | 0.080 |
Why?
|
| Paraganglioma | 1 | 2010 | 170 | 0.080 |
Why?
|
| Texas | 4 | 2023 | 6311 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 11538 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 7702 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.080 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 10331 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2023 | 8873 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1960 | 0.070 |
Why?
|
| Thoracic Neoplasms | 1 | 2010 | 337 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2006 | 500 | 0.070 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2006 | 121 | 0.070 |
Why?
|
| Taxoids | 1 | 2010 | 967 | 0.070 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.070 |
Why?
|
| Melphalan | 1 | 2009 | 834 | 0.070 |
Why?
|
| Risk Factors | 6 | 2019 | 17523 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2014 | 9180 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 423 | 0.070 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 915 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 588 | 0.070 |
Why?
|
| Breast | 3 | 2020 | 1344 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 660 | 0.060 |
Why?
|
| Wound Healing | 1 | 2010 | 815 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5159 | 0.060 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2006 | 135 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.060 |
Why?
|
| Male | 6 | 2018 | 123000 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 860 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 882 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2370 | 0.060 |
Why?
|
| Rejuvenation | 1 | 2023 | 72 | 0.050 |
Why?
|
| Cell Movement | 1 | 2010 | 2466 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2006 | 739 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 666 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4314 | 0.050 |
Why?
|
| Incidence | 3 | 2018 | 5673 | 0.050 |
Why?
|
| SEER Program | 2 | 2016 | 1000 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 305 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3251 | 0.050 |
Why?
|
| Epirubicin | 1 | 2020 | 157 | 0.050 |
Why?
|
| Ketones | 1 | 2020 | 54 | 0.050 |
Why?
|
| Furans | 1 | 2020 | 104 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 2864 | 0.050 |
Why?
|
| Time Factors | 3 | 2020 | 12926 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 75 | 0.050 |
Why?
|
| Calcium | 1 | 2006 | 1537 | 0.050 |
Why?
|
| Operative Time | 1 | 2020 | 217 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 250 | 0.040 |
Why?
|
| Triazoles | 1 | 2024 | 617 | 0.040 |
Why?
|
| Nitriles | 1 | 2024 | 906 | 0.040 |
Why?
|
| Esthetics | 1 | 2020 | 189 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2019 | 234 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2006 | 1270 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 4988 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 904 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 799 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2019 | 4804 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 467 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4298 | 0.040 |
Why?
|
| Perception | 1 | 2019 | 350 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2019 | 575 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 5377 | 0.040 |
Why?
|
| Seroma | 1 | 2016 | 79 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 1944 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 14551 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 488 | 0.030 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2015 | 49 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 371 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 332 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 3976 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 256 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 5687 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 1972 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2020 | 1996 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 3001 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 299 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1165 | 0.030 |
Why?
|
| Prone Position | 1 | 2013 | 56 | 0.030 |
Why?
|
| Trisomy | 1 | 2014 | 231 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2015 | 380 | 0.030 |
Why?
|
| Karyotyping | 1 | 2014 | 1022 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 1323 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 1301 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 4971 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 1987 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2010 | 102 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2359 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Papaverine | 1 | 2009 | 5 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6100 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2010 | 101 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2009 | 145 | 0.020 |
Why?
|
| Adolescent | 2 | 2006 | 31252 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3260 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Extremities | 1 | 2009 | 303 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3552 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 59536 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 1144 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 726 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 3842 | 0.020 |
Why?
|
| Immunoassay | 1 | 2006 | 216 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 1130 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 510 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 1304 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2315 | 0.010 |
Why?
|
| Biopsy | 1 | 2010 | 3443 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2010 | 2295 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1362 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4744 | 0.010 |
Why?
|
| Child | 1 | 2010 | 29154 | 0.010 |
Why?
|